Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kala Pharmaceuticals initiates two clinical studies
Kala has initiated dosing in its Phase III trial (KPI-121-C-001) to evaluate the safety and efficacy of LE-MPP in managing inflammation and pain associated with cataract surgery. In
Kala has initiated dosing in its Phase III trial (KPI-121-C-001) to evaluate the safety and efficacy of LE-MPP in managing inflammation and pain associated with cataract surgery. In
Proceeds from the financing will be used to augment Navitor’s proprietary drug discovery platform and accelerate the development of a pipeline of novel drugs that target cellular nutrient
GlycoMimetics is initially exploring the clinical use of the drug candidate to treat acute myeloid leukemia (AML) following preclinical studies of GMI-1271 for blood cancers and other cancers
Out of an abundance of caution, CDC is taking aggressive steps to protect the health of all involved, including providing protective courses of antibiotics for potentially exposed staff.
The patent, entitled Chemically Modified Ligase Cofactors, Donors, and Acceptors, is directed toward the use of modified ligation components to improve fidelity in nucleic acid ligation. The research
The new platform will be based on Akrivis Technologies’ proprietary Z-TECT technology that targets and detects unusually low levels of proteins and molecular targets and Leti’s Lipidot nanovector
ProMetic’s PBI-4050 was found to be safe and very well tolerated without any serious adverse events reported in any of the 5 cohorts tested. The objectives of this
The patents, which expire in 2024, claim pharmaceutical compositions comprising a form of ferric citrate having an intrinsic dissolution rate of 1.88-4.0 mg/cm2/min, and orally administrable forms of
Radient’s facility, commissioned in January, 2014, is a 20,000 square foot manufacturing plant centered around Radient’s patented, proprietary technology, Microwave Assisted Processing ("MAP"). With MAP, Radient produces natural
This opinion paves the way for Plandaí to immediately commence sales efforts in the United States. The Federal Food, Drug and Cosmetic Act requires that the US FDA